Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nike Inc (NKE) vs Sana Biotechnology Inc (SANA) Price & Performance

Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Nike Inc vs Sana Biotechnology Inc — how do they compare? Nike Inc trades at $40.64 (market cap $61.30B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Nike Inc is far larger — about 54.2× Sana Biotechnology Inc's market cap, and Nike Inc pays a 3.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

NKESANA
Market Cap
$61.30B$1.13B
Volume
8,887,180
Sector
Consumer CyclicalHealth
52-Week High
$79.17$5.92
52-Week Low
$40.75$2.68
Enterprise Value
$63.30B$1.05B
Dividend Yield
3.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nike Inc

Nike (NKE) trades at $42.11, up 0.98% on the day, showing resilience amid a challenging period. The stock faces bearish technical signals but maintains strong profitability metrics including 42.91% gross margin and 22.14% ROE. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.72 significantly exceeding the $0.11 forecast. However, revenue declined to $46.31B in 2025 from $51.4B in 2024, reflecting ongoing business headwinds.

Nike's investment case balances strong brand value and consistent earnings beats against revenue pressures and competitive challenges. The consensus price target of $50.45 suggests 20% upside potential, though technical indicators remain bearish. Key risks include China market weakness and inventory management issues, while opportunities lie in digital transformation and product innovation driving future growth.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nike Inc

NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.

Read more on NKE

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA